Lebrikizumab Maintains 48-Week Efficacy in Systemic-Naive and Experienced Atopic Dermatitis

The therapeutic landscape for moderate-to-severe atopic dermatitis has expanded rapidly with the introduction of biologics and Janus kinase inhibitors, yet achieving sustained disease control remains a challenge for many patients [1, 2]. While interleukin-13 inhibitors like lebrikizumab have demonstrated significant efficacy in randomized controlled trials, clinicians often face the practical hurdle of managing patients who have already cycled through other systemic therapies [3, 4]. These systemic-experienced patients may present with different inflammatory profiles or more recalcitrant disease, particularly in sensitive areas such as the head and neck [5]. Long-term maintenance of clinical response and the normalization of inflammatory biomarkers are critical for improving quality of life and preventing flares [6, 7]. A prospective study now provides 48-week real-world evidence on how prior systemic treatment history influences the longitudinal effectiveness of lebrikizumab, offering clinicians valuable prognostic data for sequencing therapies in refractory cases.